<DOC>
	<DOCNO>NCT00869661</DOCNO>
	<brief_summary>This 6-arm study ass efficacy safety RO5024048 ( R7128 ) combination approve dos Pegasys ( 180micrograms sc weekly ) + Copegus ( 1000/1200mg po daily ) ( SOC ) , versus SOC treatment-naive patient chronic hepatitis C , genotype 1 4 . The first 3 group receive 1 ) RO5024048 500mg bid + Pegasys + Copegus 12 week , follow SOC 12 week ; 2 ) RO5024048 1000mg bid + Pegasys + Copegus 8 week , follow SOC 16 week ; 3 ) RO5024048 1000mg bid + Pegasys + Copegus 12 week , follow SOC 12 week . After 24 week , patient 3 group achieve rapid viral response stop treatment , receive SOC 24 week . Group 4 receive RO5024048 1000mg bid + Pegasys + Copegus 12 week , follow SOC 36 week , group 5 receive SOC 48 week . Group 6 provide retreatment open-label basis patient Group 5 fail treatment . Patients receive RO5024048 1000mg bid + Pegasys + Copegus 24 week , follow SOC 24 week . The anticipated time study treatment 6-12 month .</brief_summary>
	<brief_title>A Study RO5024048 Combination With Pegasys Copegus Treatment-Naive Patients With Chronic Hepatitis C , Genotype 1 4</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis C , Chronic</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<mesh_term>Peginterferon alfa-2a</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<criteria>Adult patient , 1865 year age Chronic hepatitis C , genotype 1 4 Treatmentnaive No previous treatment interferon ribavirinbased therapy Other form liver disease HIV infection</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>